Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 955 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR 10 Ways to Provide Support During Breast Cancer Awareness Month September 27, 2019 Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over... August 31, 2022 Loving Yourself April 7, 2021 A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with... January 12, 2026 Load more HOT NEWS Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following... Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients... Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress Let’s Talk About Bubbles
